Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neuroimmunol. 2014 Jun 15;271(1-2):66-8. doi: 10.1016/j.jneuroim.2014.03.012. Epub 2014 Mar 21.

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis.

Author information

  • 1Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: william.brown@doctors.org.uk.
  • 2Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: peter.martin@addenbrookes.nhs.uk.
  • 3Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: john.thorpe@addenbrookes.nhs.uk.
  • 4Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: andrew.michell@addenbrookes.nhs.uk.
  • 5Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: ajc1020@medschl.cam.ac.uk.
  • 6Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: amandacox1@nhs.net.
  • 7Neurosciences Group, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom. Electronic address: angela.vincent@ndcn.ox.ac.uk.
  • 8Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, United Kingdom. Electronic address: msz20@cam.ac.uk.

Abstract

Autoimmune encephalitis associated with antibodies to leucine-rich glioma inactivated 1 (LGI1) is recently described and there is a lack of detailed reports on the treatment of relapsing or refractory cases and long-term outcomes. Two case reports are presented. Both cases had faciobrachial dystonic seizures (FBDS) and received rituximab after relapsing or refractory disease. Both cases achieved sustained clinical remission of up to 15 and 56 months respectively. Rituximab use allowed withdrawal of corticosteroids and was well tolerated. Randomized clinical trials are needed in LGI1 encephalitis and other autoimmune encephalitides.

Copyright © 2014 Elsevier B.V. All rights reserved.

KEYWORDS:

Autoantibody; Cognition; Encephalitis; LGI1; Rituximab; VGKC

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk